RESPOND; Risk and Evaluation of SPONDyloarthritis management
Novartis Pharma UK
About the CPD course
RESPOND; Risk and Evaluation of SPONDyloarthritis management Spondyloarthritis (SpA) refers to a group of interrelated and complex conditions; with a range of clinical manifestations. It can be challenging to diagnose; the prevalence of SpA is under-recognised; and symptoms may be mistaken for and are commonly attributed to other conditions. Management of SpA is often multifaceted and may require a coordinated approach between rheumatologists and other specialists. In this programme; the gap between current clinical practice and best-practice management is explored; including the role rheumatologists and other specialists can play in providing optimal care for patients with SpA.
Novartis is a healthcare company which strives to change the practice of medicine and aspires to approach things differently. We are passionate about what we do and the impact we have on patients and societies. We are Novartis, and we are re-imagining medicine. Our company comprises three unique divisions: Innovative Medicines, Sandoz and Alcon.